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Abstract
Canine leishmaniasis is an important zoonotic disease of dogs. The clinical outcome of infection is variable, with the
efficiency of the immune response being the key determining factor. There is now a general consensus that a predominant
Th1 immune profile in an overall mixed Th1/Th2 response is associated with resistance in dogs, and the absence of a strong
Th1 influence is associated with a progression to clinical disease. As a result, there has been a growing demand for vaccines
that can induce a specific, strong Th1 response. In this study, we measured the impact of a primary course of a newly
available LiESP/QA-21 vaccine on selected humoral and cellular markers of the canine immune response during the onset of
immunity. All vaccinated dogs developed a humoral response characterised by IgG2 production. More importantly,
vaccinated dogs developed significantly stronger cell-mediated immunity responses than did control dogs. Vaccination
induced specific cellular reactivity to soluble Leishmania antigens, with a Leishmania-specific lymphoproliferation
(p = 0.0072), characterised by an increased population of T lymphocytes producing IFN-c (p = 0.0021) and a significant
ability of macrophages to reduce intracellular parasite burdens in vitro after co-culture with autologous lymphocytes
(p = 0.0014). These responses were correlated with induction of the NOS pathway and production of NO derivatives, which
has been shown to be an important leishmanicidal mechanism. These results confirm that vaccination with LiESP/QA-21
induces an appropriate Th1-profile cell-mediated response within three weeks of completing the primary course, and that
this response effectively reduces the parasite load in pre-infected macrophages in vitro.
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Canine leishmaniasis, a vector-borne disease of dogs, is caused
by Leishmania infantum in the Mediterranean basin and is a
significant problem for the canine population of endemic areas [1].
It is transmitted in the Mediterranean area by the bite of certain
species of sand flies of the Phlebotomus (Larroussius) subgenus, and so
natural transmission can only occur in areas where competent
vector species are present [2]. Currently it is estimated that at least
2.5 million dogs are infected in southwestern Europe alone [3] and
recent publications have reported a northward spread of the
endemic area [4]. Given that canine leishmaniasis is a potentially
severe and fatal disease, it represents a source of suffering for
affected dogs and many dog owners are highly concerned about
how best they can protect their animals. Moreover, the dog is the
principle reservoir for human infection; thus a high prevalence of
this canine disease also represents a zoonotic risk [5].
In recent years, several topical repellent and insecticide
preparations with good trial data have become available and
these are able to decrease the intensity of parasite challenge
received by the dog by decreasing the number of infectious sandfly
bites received. However although these products have good short-
term efficacy data when used on an individual dog basis, some
evidence exists to suggest that this may not be maintained over the
longer term [6]. Even with correct use, these products cannot
prevent all infectious bites and there is still a need for further
control measures [7].
The outcome of the infection in individual dogs is highly
variable and not all dogs which are infected will develop the
disease [8]. Some dogs will completely clear the infection, some
will remain subclinically infected, while some will develop clinical
disease of varying severity from mild papular skin disease to severe
generalised disease characterised by renal failure and eventually
death [9,10].
Studies on canine leishmaniasis have somewhat clarified the risk
factors determining the likelihood of disease developing after
infection [1,3]. However it has become clear that the final
outcome of infection depends mainly on the efficiency of the dog’s
immune system [3,11]. In murine cutaneous leishmaniasis, it has
been demonstrated that there is a clear dichotomous immune
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response: T helper 1 (Th1) responses are associated with
protection while T helper 2 (Th2) responses are associated with
the development of disease [12]. In contrast, data from human
visceral leishmaniasis cases and the murine model of visceral
leishmaniasis have shown that this Th1/Th2 dichotomy is lacking,
and a mixed response is essential for protection [13–15]. Although
dogs which remain asymptomatic after infection with L. chagasi
( = L. infantum) develop a predominantly Th1 profile response,
whereas oligosymptomatic and symptomatic dogs present a Th2
profile [16], a clear dichotomous Th1/Th2 pattern is also lacking
in this species [17]. However, despite the fact that the situation is
extremely complex, it is now widely accepted that the protective
canine immune response is mediated by a dominant CD4+ Th1
influence in an overall mixed cellular response [18,19]. This
protective response is believed to be mediated by the induction of
inducible nitric oxide synthase (iNOS) in macrophages upon
stimulation by Th1 cytokines such as interferon gamma (IFN-c).
This results in a decreased production of arginase, and
consequently of the polyamides that are essential for parasite
growth and survival in the macrophage, and an increased
production of leishmanicidal nitric oxide (NO) derivatives
[20,21]. In addition, in vitro studies propose that while iNOS
activity can be considered as an essential effector mechanism to
prevent multiplication of Leishmania amastigotes, the NO derivative
produced may have additional roles including immunoregulatory
functions [22].
Because of this pivotal role for the immune system, several
authors have expressed the opinion that an effective vaccine
against canine leishmaniasis would be the best control strategy for
both canine and human disease [7,23].
Two canine vaccines have been available for some time now in
Brazil [11]. However, until the recent launch of the LiESP/QA-21
vaccine (CaniLeish, Virbac, France), there were no vaccines
against Leishmania available in Europe. With any new vaccine, and
especially one that is the first of its kind, it is important to
understand as much as possible about the mechanism of its action
on the dog’s immune response and to study known markers of
resistance to disease. Indeed investigation of such parameters has
recently been proposed as representing an important supplementary
data set when assessing any candidate vaccine for canine
leishmaniasis [11]. The aim of the study presented here was to
follow selected humoral and cellular markers of the immune
response in dogs vaccinated with LiESP/QA-21 vaccine during the
establishment of the immune response, and specifically to assess if an
effective Th1-dominated profile could be generated.
Materials and Methods
Ethics Statement
The Virbac Ethical Committee approval confirms that this
study was carried out in accordance with the G.R.I.C.E. ‘‘Ethical
Committee Regulation applied to animal experimentation’’
guidelines (implemented in France in 2007).
Animals’ Characteristics
20 conventional Beagle dogs (10 male and 10 female) aged 6
months +/21week on the day of the first vaccination were
randomly assigned to two groups (vaccinated and control)
according to their weight, sex and litter of birth. There were 5
males and 5 females per group.
All animals were previously vaccinated with conventional
vaccinations against Distemper virus, Adenovirus, Parvovirus,
Parainfluenza virus and Leptospira.
They were housed in controlled conditions, and dewormed with
nitroscanate (Troscan, Virbac, France) 1 week prior to the date of
the first administration of the LiESP/QA-21 vaccine.
Vaccine and Vaccination Protocol
The LiESP/QA-21 vaccine is authorised in the European
Union under the trade name CaniLeish (Virbac, France). It is
composed of purified excreted-secreted proteins of Leishmania
infantum (LiESP), produced by means of a patented cell-free,
serum-free culture system invented by the IRD (Institut de
Recherche pour le Développement) [24], and adjuvanted with
QA-21, a highly purified fraction of the Quilaja saponaria saponin.
The doses used in this study were formulated at 100 mgESP and
60 mg QA-21. This is consistent with the minimum accepted levels
in commercially available doses.
Dogs in the vaccinated group were given one dose of the
LiESP/QA-21 vaccine every 21 days for a total of three doses.
Dogs in the control group did not receive any vaccination.
Analyses and Schedule
Serology testing of the humoral immune
response. ELISA testing was performed on the day of each
vaccination (D0, D21, D42) and also two weeks after the last
vaccine (D56) to dose the level of IgG1 and IgG2 antibodies to
both LiESP and also specifically to Parasite Surface Antigen (PSA),
which is a major antigenic component of LiESP. Blood was
collected in uncoated tubes and the serum separated before
performing the analyses.
Briefly, the technique is performed as follows. A NUNC
Maxisorp plate is coated with either 0.1 mg ESP or 0.1 mg PSA per
well in carbonate buffer for 90 minutes at 35–37uC. Non-specific
sites are blocked with PBS-Tween 0.5%-milk 5% for 90 minutes at
35–37uC. Then serial three-fold dilutions of the serum to be tested
in PBS-milk 0.5% buffer, beginning at 1/150, are added to the
plate. After 60 minutes of incubation at 35–37uC any antibodies
fixed to the ESP or PSA respectively are revealed with a specific
peroxydase-conjugated polyclonal anti-IgG1 or anti-IgG2 second-
ary antibody (Bethyl Laboratories, Montgomery, USA) and ABTS
colouration. The titre corresponds to the first dilution with an
optical density at 405 nm inferior to 0.4.
Author Summary
The dog is the principle reservoir of Leishmania infantum, a
parasite spread from dog to dog by a sandfly vector. The
reduction of canine leishmaniasis is therefore a key factor
in the overall management of the epidemiology of this
parasite. There is also a need for effective prevention on
welfare grounds because of the clinical severity of this
potentially fatal disease in dogs. The key factor determin-
ing the outcome of infection in dogs is the ability to
mount a Th1-dominated immune response, because this is
more effective against intracellular pathogens such as L.
infantum. Until now, in Europe, only measures to reduce
sandfly bites have been available, and for many years there
has been a strong demand for a vaccine that provides
specific and effective immunity. The recent launch of the
first European canine leishmaniasis vaccine (CaniLeish) has
provided a means to achieve this, but data on its impact
on the dog’s immune system are required. The data
presented here demonstrate the specific stimulation of an
effective Th1-dominated anti-L. infantum response within
three weeks of the administration of the vaccine, and
provides a basis for the understanding of the mode of
action of this new tool.
LiESP/QA-21 Stimulates Th1 Cellular Immunity
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Cellular immune response assays. The three cell-mediat-
ed immunity tests, as described below, [Lymphoblastic Transfor-
mation Test (LTT), IFN-c Enzyme-Linked Immunospot Assay
(ELISpot) and Canine Macrophage Leishmanicidal Assay
(CMLA)] were performed three weeks after the third vaccination
(D62). The CMLA was also performed at baseline on the day of
the first vaccination (D0)
LTT: This assay is designed to reveal the ability of the specific
memory T cells produced as a result of vaccination to proliferate
after being exposed to Soluble Leishmania Antigens (SLA). It was
performed in a manner similar to that previously described
[25,26].
Briefly, heparinized blood samples are fractionated by centri-
fugation over lymphocyte separation medium. Peripheral Blood
Mononuclear Cells (PBMC) obtained are incubated at a density of
106 cells/ml for 5 days (37uC, 5% CO2) in presence of either
10 mg/ml Concanavalin A (ConA), or 10 mg/ml SLA, or with
medium alone. The cells are pulsed during the last 24 h with
10 mM 5-bromo-2-deoxyuridine (BrdU), which is incorporated
into the DNA of proliferating cells. BrdU incorporation is
determined with a specific ELISA system (GE Healthcare,
Chalfont St. Giles, UK), using peroxydase-labelled anti-BrdU
antibodies which are in turn detected by a substrate reaction using
3,395,59-tetramethylbenzidine. Absorbance values at 450 nm
correlate directly to the amount of DNA synthesis and thereby
to the number of proliferating cells in culture. The results are
expressed as the lymphoproliferation index, which is the ratio of
the mean optical density obtained for the SLA stimulated samples
compared to the mean optical density obtained for the non-
stimulated samples. ConA is used as a positive control and the
medium alone is used as a negative control.
ELISpot: This assay is designed to determine the proportion of
T cells that release IFN-c after stimulation with SLA in order to
quantify the level of stimulation of a specific Th1 polarity immune
memory response. It was performed in a manner similar to that
previously described [27]. Heparinized blood samples are
fractionated by centrifugation over lymphocyte separation medi-
um. The PBMCs obtained are incubated at a density of 106 cells/
ml for 3 days in multiscreen HTS filter plates (Millipore, Billerica,
USA) previously coated with canine IFN-c capture antibody
(R&D System, Minneapolis, USA), in presence of 10 mg/ml
ConA, or 10 mg/ml SLA antigens, or with medium alone, in a
humidified 37uC CO2 incubator. The quantity of IFN-c is
revealed with a specific biotinylated antibody and incubation with
Streptavidin-AP and the BCIP/NBT Chromogen (R&D System,
Minneapolis, USA). The number of specific spots is determined by
an automated ELISpot reader. ConA is used as a positive control
and the medium alone is used as a negative control. The data
presented are the number of spots per 26105 cells after stimulation
with SLA minus the equivalent value obtained with the negative
control using medium alone.
CMLA: This assay is designed to determine the ability of
monocyte-derived canine macrophages to kill Leishmania parasites
in a co-culture system due to the stimulation of iNOS expression
and the resulting production of NO derivatives when the
macrophage is exposed to autologous lymphocytes derived from
canine PBMC. It was performed in a manner similar to that
previously described [28–30].
Briefly, monocytes separated from lymphocytes by adherence,
are cultured at a density of 26105 cells per well at 37uC and 5%
CO2 for 6 days in complete RPMI 1640 medium containing
25 mM Hepes.
After 6 days of culture, monocyte-derived macrophages are
infected with stationary growth phase Leishmania infantum
(MCAN/82/GR/LEM 497) promastigotes at a ratio of 1:5 for
5 h; then the cells are washed and fresh medium is added for 24 h
and this point considered as time zero. The infected cells (t0) are
washed and incubated alone or in the presence of 105 autologous
lymphocytes for 72 h in complete medium containing additionally
10 mM HEPES and 561025 M 2-mercaptoethanol. After 72 h of
co-culture, the lymphocytes are then removed by several gentle
washings, the cell free supernatants are conserved for analysis and
the macrophages are fixed in order to evaluate the leishmanial
killing. One part of the fixed macrophages is stained with Giemsa
and the leishmanicidal activity is determined microscopically by
counting in triplicate the number of intact parasites per 100 cells
with or without lymphocytes (inhibition of parasitic index).
The other part of the fixed macrophages is used to evaluate the
inducible nitric oxide synthase (iNOS) expression by immunola-
belling with NOS specific antibodies, as described previously [29].
The production of NO2 (involved in the NO cascade) is
determined in the culture supernatants using the modified Griess
reference technique [31]. When evaluating this leishmanicidal
activity test, a result is considered as successful, when the %
inhibition of the parasitic index (CMLA) is associated with the
activation of the NO pathway and directly correlated with a
significant increase of iNOS expression and the production of NO
derivatives.
Statistical Analyses
All statistical tests were performed using the SAS v9.1 software,
and for all analyses the significance threshold was set at p = 0.05.
Intergroup comparisons of the results of the CMLA on D0 and
the CMLA, LTT and ELISpot assays on D62 were performed
using a Wilcoxon test.
Results
Serology Testing of the Humoral Immune Response
Over the course of the study, all LiESP/QA-21 vaccinated dogs
developed an IgG2 response to both ESP (range 1/1350 to 1/
4050) and, in particular, to PSA (range 1/450 to 1/4050). See
Figures 1 and 2.
All vaccinated dogs also developed an IgG1 response to ESP by
the end of the study (range 1/450 to 1/4050) whereas only four of
the ten vaccinated dogs developed positive IgG1 titres to PSA by
day 56 (range 1/450 to 1/1350). See Figures 1 and 2. The
Figure 1. Progression in log-transformed anti-ESP IgG1 and
IgG2 titres during the onset of immunity. The data presented here
are the means of the log-transformed titres. The titre is taken to be the
first dilution with an optical density of less than 0.4 measured at
405 nm. The sera were tested using an ESP-coated ELISA at days 0, 21,
42 and 56. The ESP used was identical in profile to the antigen of the
vaccine.
doi:10.1371/journal.pntd.0001683.g001
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serological response induced as a result of vaccination with
LiESP/QA-21 is therefore biased towards an IgG2 profile.
No dogs in the control group developed positive titres at any
point throughout the course of this study.
Cellular Immune Response Assays
LTT. The cells of all animals in both vaccinated and control
groups were able to respond effectively to the non-specific positive
control stimulation with ConA (data not shown).
When SLA was used to determine the Leishmania-specific
lymphoproliferation index, the median index in the control group
was 1, equivalent to background cell turnover, indicating that no
specific response was present.
In the vaccinated group, the median index was 1.2. This is
significantly different from the control group (p = 0.0072) con-
firming the development of a specific T cell response to L. infantum
parasites as a result of vaccination with the LiESP/QA-21 vaccine.
See Figure 3.
ELISpot. The cells of each animal, in both groups, produced
IFN-c after stimulation with ConA (data not shown).
Once again, the control group did not show any specific
response to stimulation with SLA (mean number of spots per
26105 cells was zero).
In the vaccinated group the mean number of spots per 26105
cells was five, demonstrating the ability to generate IFN-c
producing T cells specific to L. infantum parasites as a result of
vaccination with the LiESP/QA-21 vaccine. This is also signifi-
cantly different from the control group (p = 0.0021). See Figure 4.
CMLA. Data obtained from these leishmanicidal experiments
demonstrate that after LiESP/QA-21 immunization, the antil-
eishmanial effect obtained is associated with a significant NO2
generation and positive iNOS expression by macrophages when
compared to the NO2 production by control macrophages.
At baseline (day 0) the assay did not detect any significant
activity in any of the dogs in either vaccinated or control groups,
with all values in the three parameters being low for every dog.
There was no statistical difference between the vaccinated and
control groups at baseline for the CMLA index (p = 0.9701) and
iNOS activity (p = 0.6002). However, the NO2 production was
higher in the vaccinated group than in the control group
(p = 0.0335). This was then taken into account for the analysis of
the data on day 62 by performing an additional analysis of co-
variance. (3 weeks after the third dose of the vaccine). See Figure 5.
On day 62, the vaccinated group had significantly higher results
than the control group in all three parameters (p = 0.0014). Taking
into account the heterogeneity in the values from D0, the NO2
production was still significantly higher at D62 in the vaccinated
group in comparison to that seen in the control group (p,0.0001).
In terms of temporal progression, both groups demonstrated a
rise in the values measured by these tests. However only the
vaccinated dogs achieved values that were above the threshold in
all three tests (See figure 5).
It is evident from these results that successful vaccination with
the LiESP/QA-21 vaccine induces protective antigen-activated T
cells producing Th1-derived cytokines such as IFN-c. These cells
are capable of activating autologous infected macrophages to kill
intracellular L. infantum parasites by means of induction of iNOS
and the production of nitric oxide (NO) derivatives.
Figure 2. Progression in log-transformed anti-PSA IgG1 and
IgG2 titres during the onset of immunity. The data presented here
are the means of the log-transformed titres. The titre is taken to be the
first dilution with an optical density of less than 0.4 measured at
405 nm. The sera were tested using a PSA-coated ELISA at days 0, 21, 42
and 56. PSA is a dominant antigen in ESP and therefore a key antigen in
the vaccine.
doi:10.1371/journal.pntd.0001683.g002
Figure 3. Lymphoproliferation index 3 weeks after the
completion of the primary vaccination course. This assay detects
the ability of the specific T cells produced as a result of vaccination to
proliferate after being exposed to Soluble Leishmania Antigens (SLA).
The lymphoproliferation index is the ratio of the mean optical density
obtained for the SLA stimulated samples compared to the mean optical
density obtained for the non-stimulated samples using a BrdU specific
ELISA system.
doi:10.1371/journal.pntd.0001683.g003
Figure 4. ELISpot detection of IFN-c secreting lymphocytes 3
weeks after the completion of the primary course. This assay
detects the ability of lymphocytes to secrete IFN-c after specific
stimulation with SLA by detecting spots (which represent a clone of
cells secreting IFN-c) using specific biotinylated antibodies and an
automated ELISpot reader. The data presented here are the number of
spots per 26105 cells after stimulation with SLA minus the equivalent
value obtained with the negative control using medium alone.
doi:10.1371/journal.pntd.0001683.g004
LiESP/QA-21 Stimulates Th1 Cellular Immunity
www.plosntds.org 4 June 2012 | Volume 6 | Issue 6 | e1683
Discussion
Resistance to canine leishmaniasis is associated with a
predominance of Th1 cytokines, such as IFN-c, favouring a Th1
bias in an overall mixed Th1/Th2 response [18,32]. By contrast,
progression to disease, and potentially death, is associated with a
predominance of Th2 cytokines and a marked humoral response
in the absence of a strong Th1 response [19].
In mice it has been shown that antibodies of the IgG1 subtype
are associated with a Th2 response and antibodies of the IgG2
subtype are associated with a Th1 response [33]. However, despite
some initial reports suggesting the same happens in dogs, the
IgG1/IgG2 ratio does not appear to be correlated with resistance
to development of the disease [34].
Notwithstanding the recent evidence refuting the direct
relationship between the IgG1/IgG2 ratio and Th1/Th2 balance,
it is still possible that the IgG2 response to PSA could ultimately
prove relevant to some degree. IgG2a antibody, which is effective
in opsonisation and complement fixation, may still have a direct
role by targeting individual amastigotes that are released from
infected macrophages [34]. A recent investigation looked at the
activity of sera from dogs vaccinated with a prototype LiESP
vaccine formulated with the MDP adjuvant [35]. It found that the
IgG2 induced by LiESP vaccination resulted in a functionally
active serum that was leishmanicidal to both promastigotes and
amastigotes, that had a strong inhibitory effect on the in vitro
growth of both stages and, importantly, that pre-treatment of
amastigotes by the serum led to a significant inhibition of in vitro
infectivity to canine macrophages. The authors concluded that
even if the Th1-dominated cell-mediated immune response is the
primary mechanism of resistance, it is possible that IgG2 may play
a role in the complex overall immune responses that lead to
resistance in the dog. It is therefore of interest to note that in the
present study we had a clear bias towards IgG2 production and
that this was most obvious in the response against PSA. The PSA
of L. infantum has been specifically demonstrated to have a role in
macrophage invasion [36], and this fact, taken in association with
the findings of Bourdoiseau et al, [35] suggests that the ELISA
results presented here should not be discounted. Further work to
explore this in more detail could be very interesting, as would be
an examination of the antibody response profile to vaccination
with LiESP/QA-21 using the newer canine IgG1-4 monoclonal
antibodies, even if these have not yet been correlated to a specific
Th1/Th2 profile [34].
It should also be noted that even if raised titres to ESP are
achieved after 2 injections, the elevated IgG2 titres to PSA are
obtained only after the third injection. This is due to a
combination of dogs which had only low titres after the second
injection displaying augmented titres after the third, and some
dogs which were still negative on this test after the second injection
displaying detectable titres for the first time after the third.
The data presented in this study regarding cellular immunity
parameters are particularly interesting and, according to the
current state of knowledge of the immunology of this disease, they
are the more applicable results. Although there appears to be a
clear consensus that the Th1-dominated profile within a mixed
Th1/Th2 response is the desirable profile for protection of the dog
[37], the overall in vivo response is clearly complex and it is not
possible to correlate individual markers of this response with
absolute resistance to disease in a particular dog. Therefore it is
important to take all of the parameters together to obtain a sense
of the overall direction of the response. This concept was clearly
presented in a recent paper by Reis et.al., where the concept of a
dynamic spectrum in the immune response was introduced [11].
Figure 5. CMLA assay: inhibition of the macrophage parasitic
index, iNOS activity and production of NO derivatives. Panel A
is a comparison of the ability of the macrophages to inhibit parasite
multiplication before vaccination (D0) and 3 weeks after completion of
the primary course (D62). It demonstrates the increase in the inhibition
of the macrophage parasite index as a result of vaccination. Panel B Is a
comparison of the rate of expression of iNOS in the macrophages
before vaccination (D0) and 3 weeks after completion of the primary
course (D62). Panel C is a comparison of the rate of production of NO
derivatives from the macrophages to before vaccination (D0) and 3
weeks after completion of the primary course (D62). When these three
measurements are consistent, this provides evidence of an increased
NO-mediated pathway of parasite killing as a result of vaccination.
doi:10.1371/journal.pntd.0001683.g005
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In the present study it is clear that use of the LiESP/QA-21
vaccine induces a subset of Leishmania-specific T cells as evidenced
by the specific proliferative response upon stimulation with crude
extracts of the parasite. We also showed that this specific T cell
population has a dominant Th1 profile as evidenced by the ability
to secrete IFN-c upon stimulation with SLA. Although there is no
single cell-mediated immunity marker that is directly correlated
with protection in individual patients, much data has accumulated
to support IFN-c production from stimulated PBMCs as a key
requirement. In a study of the expression of 6 cytokine markers
(IFN-c, TNF-a, IL-2, IL-4, IL-5 and IL-10) in the memory T-cell
response to SLA stimulation in humans, only IFN-c production was
correlated with cured/resistant patients [38]. Further studies have
confirmed that this is also applicable to dogs, since the ability of
canine PBMCs to proliferate and produce IFN-c at high levels after
stimulation with SLA was associated with a resistant profile in
contrast to polysymptomatic and non-infected control dogs [39,40].
Care must be taken in the over-interpretation of a single
parameter such as IFN-c as we know that it operates as part of a
complicated network of regulatory and counter-regulatory inter-
actions involving multiple cytokines [41]. Nonetheless, the CMLA
results presented here further demonstrate that the IFN-c
production was functionally active in vitro where it stimulated
autologous macrophages to kill L. infantum parasites. This finding is
important, as it appears that although IFN-c production from
stimulated PBMCs is the key marker of the correct response, other
co-factors such as TNF-a are also needed to effect the stimulation
that results in effective leishmanicidal activity in the macrophage
[19]. In murine and human macrophages, TNF-a and IFN-c act
synergistically to induce the elimination of Leishmania amastigotes
[42,43], and this has been confirmed to be the same in dogs also
[11]. Recent studies have also demonstrated that in the presence of
high levels of IL-10, even significant IFN-c responses may not be
effective and the IL-10/IFN-c ratio could be relevant [41].
Unfortunately due to the lack of an available validated assay for
canine IL-10 this was not possible during this study.
The data presented here are consistent with an overall effective
response. Furthermore, when the CMLA results are considered
there is a consistent clear correlation between induction of iNOS,
production of NO derivatives and leishmanicidal effect. This
suggests that iNOS positive activated macrophages were able to
control the multiplication of Leishmania parasites and to kill them.
This is consistent with the current views on the mechanism of
parasite killing or parasite maintenance in the macrophage,
whereby stimulation of macrophages by Th1 cytokines favours
iNOS metabolism of L-arginine to leishmanicidal NO [44], but
stimulation by Th2 cytokines leads to an alternative activation
pathway in the macrophages. This favours arginase metabolism of
L-arginine, resulting in the synthesis of polyamines which sustain
the growth of the intracellular parasite burden [45]. The critical
role played by induction of NO production and the oxidative burst
in killing Leishmania parasites has been well documented in recent
years and was elegantly demonstrated in a Syrian hamster model
which showed that the inability to produce NO due to a lack of
iNOS expression resulted in the inability to control intracellular L.
donovani [46]. The pivotal role of NO production in dog
macrophages had also been demonstrated in a previous study
showing that after successful chemotherapy the macrophage
regained the ability to control the parasites via an IFN-c mediated
stimulation of the NO synthase pathway [30]. In light of this, it
could also have been interesting to have looked for evidence of
alternatively activated macrophages which are tolerant to the
parasite, or to have investigated the production of Th2 cytokines,
such as IL-4 and IL-10, that are able to down-regulate the
antileishmanial effect of macrophages by decreasing NO produc-
tion [47].
It is also interesting to note the rise in the CMLA results in the
control group during the study. This is not entirely surprising, as it
is well recognised that the maturation of the cell-mediated arm of
the adaptive immune response is slower than that of the humoral
response ability [48], and this increase may simply reflect
progressive maturity of the immune response in these dogs
between the ages of 6 and 9 months. Nevertheless, despite the
small rise in the control group, the clear difference between the
groups over the course of this study as a result of the application of
the LiESP/QA-21 vaccine adds another piece of evidence
supporting the expected efficacy of the vaccine in dogs.
It must also be noted that such data cannot represent the full
picture of the complex immune response to L. infantum. Other
factors are also in play in the context of the intact immune system
of a live animal. This means that such data can never completely
replace in vivo challenge studies. However, in the context of
attempts to reduce the use of experimental animals in virulent
challenge studies, models such as this one can provide a very
valuable database and they have been recommended as a rational
way to explore the activity of any potential vaccine against canine
leishmaniasis [11]. Despite this obvious limitation, the overall
result here clearly demonstrates that the presence of sensitized
lymphocytes, induced as a result of vaccination with LiESP/QA-
21, enhanced the antileishmanial activity of autologous macro-
phages and enabled them to kill L.infantum parasites in vitro, via the
nitric oxide pathway. This supports the hypothesis that this
vaccine could be expected to be efficacious at reducing parasite
loads in vivo.
Conclusion
The results presented in this study confirm that vaccination of
dogs with LiESP/QA-21 vaccine is capable of inducing a Th1
profile cellular response, within 3 weeks of the primary vaccine
course, which in turn is effective in vitro at reducing the parasite
load in pre-infected autologous macrophages. Until in vivo
challenge studies are reported, this data provides an understanding
of the mechanism and onset of immunity induced by use of
LiESP/QA-21 vaccine, which is the first of its type commercially
available in Europe.
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(2009) Effective humoral and cellular immunoprotective responses in LiESAp-
MDP vaccinated protected dogs. Vet Immunol Immunopathol 128: 71–78.
36. Kedzierski L, Montgomery J, Bullen D, Curtis J, Gardiner E, et al. (2004) A
Leucine-Rich Repeat Motif of Leishmania Parasite Surface Antigen 2 Binds to
Macrophages through the Complement Receptor 3. J Immunol 172: 4902–
4906.
37. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L (2008) Canine
leishmaniosis – new concepts and insights on an expanding zoonosis: part one.
Trends Parasitol 24: 324–330.
38. Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, et al. (2010) Evaluation
of ex vivo human immune response against candidate antigens for a visceral
leishmaniasis vaccine. Am J Trop Med Hyg 82: 808–813.
39. Chamizo C, Moreno J, Alvar J (2005) Semi-quantitative analysis of cytokine
expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol
103: 67–75.
40. Carrillo E, Ahmed S, Goldsmith-Pestana K, Nieto J, Osorio Y, et al. (2007)
Immunogenicity of the P-8 amastigote antigen in the experimental model of
canine visceral leishmaniasis. Vaccine 25: 1534–1543.
41. Alexander J, Bryson K (2005) T helper (h) 1/Th2 and Leishmania: paradox rather
than paradigm. Immunology Letters 99: 17–23.
42. Vouldoukis I, Riveros-Morenot V, Dugas B, Ouaaz F, Becherel P, et al. (1995)
The killing of Leishmania major by human macrophages is mediated by nitric
oxide induced after ligation of the FccRII/CD23 surface antigen. Proc Natl
Acad Sci USA 92: 7804–7808.
43. Nacy CA, Nelson BJ, Meltzer MS, Green SJ (1991) Cytokines that regulate
macrophage production of nitrogen oxides and expression of antileishmanial
activities Res Immunol 142: 573–576.
44. Wanasen N, Soong L (2008) L-arginine metabolism and its impact on host
immunity against Leishmania infection. Immunol Res 41:15–25.
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